636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy

Authors: Kong, B.Y., Lin, F.P-Y., Espinoza, D., Thavaneswaran, S., Meniawy, T., Desai, J., Harrup, R., Selva-Nayagam, S., Charakidis, M., Cuff, K., Sebastian, L., Lee, C.K., Chinchen, S., Thomas, D.M., Ballinger, M.L., Simes, J., Goldstein, D.

Source: In Annals of Oncology September 2024 35 Supplement 2:S505-S505

623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12

Authors: Lin, F.P., Mersiades, A., Lee, J., Xu, W., Chinchen, S., Charakidis, M., Thavaneswaran, S., Hughes, B.G.M., Underhill, C.R., Takhar, H.S., Harrup, R., Nagrial, A., Millward, M., Desai, J., Espinoza, D., Lee, C.K., Solomon, B.J., Simes, J., Pavlakis, N., Thomas, D.

Source: In Annals of Oncology September 2024 35 Supplement 2:S498-S498

1134P BRAF codon 600 mutations in patients diagnosed with melanoma in the UK; An audit to assess variation in mutation frequency & methods between clinical testing centres

Authors: Charakidis, M., Backen, A., Wallace, A.J., Blackhall, F.H., Wang, X., Lorigan, P.

Source: In Annals of Oncology September 2020 31 Supplement 4:S760-S760

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.